Paper40596223
Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma.
Cocito C and 5 others. Sci Rep, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma. Papers, record 40596223. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40596223
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioblastoma | Major topic |
| Brain Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Dose Fractionation, Radiation | |
| Tumor Microenvironment | |
| Humans | |
| Combined Modality Therapy | |
| Disease Models, Animal | |
| Mice, Inbred C57BL | |
| Cell Proliferation |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| UL1 TR001873 | NCATS NIH HHS | United States | UL1TR001873 | PubMed | NIH RePORTER |
| UL1 TR002384 | NCATS NIH HHS | United States | UL1TR002384 | PubMed and NIH | NIH RePORTER |
| UL1TR002384 | NCATS NIH HHS | United States | UL1TR002384 | PubMed and NIH | NIH RePORTER |
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17051156 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. | Nature | 2006 | https://conductscience.org/library/papers/17051156 | PubMed |
| 2 | 24045166 | Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. | J Neuroimmunol | 2013 | https://conductscience.org/library/papers/24045166 | PubMed |
| 3 | 25408172 | The soft agar colony formation assay. | J Vis Exp | 2014 | https://conductscience.org/library/papers/25408172 | PubMed |
| 4 | 22483738 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. | Int J Radiat Oncol Biol Phys | 2012 | https://conductscience.org/library/papers/22483738 | PubMed |
| 5 | 28598415 | DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. | Nat Commun | 2017 | https://conductscience.org/library/papers/28598415 | PubMed |
| 6 | 16972896 | CNS immune privilege: hiding in plain sight. | Immunol Rev | 2006 | https://conductscience.org/library/papers/16972896 | PubMed |
| 7 | 27532020 | A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. | J Immunother Cancer | 2016 | https://conductscience.org/library/papers/27532020 | PubMed |
| 8 | 23462419 | Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/23462419 | PubMed |
| 9 | 26406148 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406148 | PubMed |
| 10 | 32968155 | Molecular subtyping of glioblastoma based on immune-related genes for prognosis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32968155 | PubMed |
| 11 | 27358487 | Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/27358487 | PubMed |
| 12 | 25053711 | Epidemiologic and molecular prognostic review of glioblastoma. | Cancer Epidemiol Biomarkers Prev | 2014 | https://conductscience.org/library/papers/25053711 | PubMed |
| 13 | 31238970 | Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31238970 | PubMed |
| 14 | 31815646 | Immune landscapes associated with different glioblastoma molecular subtypes. | Acta Neuropathol Commun | 2019 | https://conductscience.org/library/papers/31815646 | PubMed |
| 15 | 17440099 | Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. | Cancer Res | 2007 | https://conductscience.org/library/papers/17440099 | PubMed |
| 16 | 32437507 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32437507 | PubMed |
| 17 | 24777500 | Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. | Cancer Immunol Res | 2013 | https://conductscience.org/library/papers/24777500 | PubMed |
| 18 | 16580493 | Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. | Int J Radiat Oncol Biol Phys | 2006 | https://conductscience.org/library/papers/16580493 | PubMed |
| 19 | 25855793 | Human DNA Exonuclease TREX1 Is Also an Exoribonuclease That Acts on Single-stranded RNA. | J Biol Chem | 2015 | https://conductscience.org/library/papers/25855793 | PubMed |
| 20 | 28697342 | Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28697342 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42375374 | Meningeal immunity and "Interstitial" therapy: a new paradigm for immunotherapy in glioblastoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42375374 | PubMed |
| 42196502 | The Double-Edged Sword: How Radiotherapy Shapes the Tumor Immune Microenvironment to Modulate Responses to Checkpoint Inhibitors. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196502 | PubMed |
| 42038016 | Myeloid-Derived Suppressor Cells and Radiotherapy: Regulation and Clinical Implications. | J Cancer | 2026 | https://conductscience.org/library/papers/42038016 | PubMed |
| 41974019 | IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma. | Cancer Res | 2026 | https://conductscience.org/library/papers/41974019 | PubMed |
| 41892350 | Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026. | Cells | 2026 | https://conductscience.org/library/papers/41892350 | PubMed |
| 41403943 | A case report of advanced pancreatic neuroendocrine carcinoma with Ki67 80%, CPS 0, and pMMR achieving durable complete response for over 7 years after combination immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41403943 | PubMed |
| 41374979 | Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41374979 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40596223
GET https://conductscience.org/api/papers/v1/40596223/references?page=2